Search

Your search keyword '"Lindeman N"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Lindeman N" Remove constraint Author: "Lindeman N"
111 results on '"Lindeman N"'

Search Results

1. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.

14. COMBINED EUS-PFT

15. Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

20. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

23. One patient, two lymphomas.

24. Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples.

25. Clinicogenomic characterization of inflammatory breast cancer.

26. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.

27. Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.

29. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma.

30. MatchMiner: an open-source platform for cancer precision medicine.

31. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

32. Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior.

33. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups.

34. Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).

35. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

36. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

37. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.

38. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.

39. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

40. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.

41. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas.

42. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.

43. HPV-16 in a distinct subset of oral epithelial dysplasia.

44. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.

45. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study.

46. Primary Endometrial Marginal Zone Lymphoma (MALT Lymphoma): A Unique Clinicopathologic Entity.

47. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.

48. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.

49. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.

50. Impact of a prospective review program for reference laboratory testing requests.

Catalog

Books, media, physical & digital resources